The bio-erodible implant is administered into the eye’s vitreous cavity with a 25-gauge applicator. Credit: elenavolf / Shutterstock. · Medical Device Network · elenavolf / Shutterstock. Perfuse ...

Even with good control of the underlying uveitis through systemic immunomodulatory therapy, uveitic macular edema often ...

June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty ...

Please provide your email address to receive an email when new articles are posted on . According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual ...

Outcomes for patients with diabetic macular edema did not have treatment with intravitreal dexamethasone implants affected by their glycosylated hemoglobin. Patients who have diabetic macular edema ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BARCELONA, Spain — A subgroup analysis of the DAVIO 2 ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...